Esaxerenone - Daiichi Sankyo
Alternative Names: CS-3150; MINNEBRO; XL-550Latest Information Update: 05 Nov 2023
At a glance
- Originator X-Ceptor Therapeutics
- Developer Daiichi Sankyo Company
- Class Antihyperglycaemics; Antihypertensives; Pyrroles; Small molecules; Sulfones
- Mechanism of Action Mineralocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hypertension
- Phase III Diabetic nephropathies
- No development reported Cardiovascular disorders; Heart failure
Most Recent Events
- 08 Nov 2019 Efficacy and safety data from the phase III ESAX-DN trial in Diabetic nephropathies presented the annual meeting of the American Society of Nephrology (ASN-2019)
- 04 Sep 2019 Daiichi Sankyo completes a phase I bioequivalence trial in in Japan (JapicCTI-194837)
- 28 Jul 2019 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in USA (PO)